Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class PotentialPRNewsWire • 03/30/22
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kgBusiness Wire • 03/29/22
FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older PeopleBenzinga • 03/29/22
FDA authorizes 2nd booster shots of Pfizer and Moderna COVID-19 vaccines for older adults and immunocompromised peopleBusiness Insider • 03/29/22
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and OlderBusiness Wire • 03/29/22
Dow Jones Newswires: Pfizer's etrasimod hits goals again in ulcerative colitis studyMarket Watch • 03/29/22
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class PotentialBusiness Wire • 03/29/22
How Pfizer's $6.7 Billion Arena Pharmaceuticals Buyout Could Work for InvestorsThe Motley Fool • 03/26/22
ViiV Healthcare Announces Label Update for Its Long-Acting HIV Treatment, Cabenuva (cabotegravir, rilpivirine), to Be Initiated With or Without an Oral Lead-in PeriodBusiness Wire • 03/24/22
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older AdultsBusiness Wire • 03/24/22